drugset / Trial / NCT07324616
A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
NaParallel-groupOpen-labelTreatment
Summary
The purpose of this Phase 1 study is to understand and compare the amount of EDG-7500 in the blood after a single dose in participants with different levels of liver function impairment versus participants with normal liver function. The safety of EDG-7500 in adult participants with different levels of liver function impairment will also be evaluated in this study.
Timeline
- Start
- 2026-01-26
- Primary completion
- 2026-05
- Completion
- 2026-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EDG-7500 | Unknown | — | Oral |
Indications
No indication recorded.